Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle

This study has been completed.
Ferring Pharmaceuticals
Information provided by (Responsible Party):
OVO R & D Identifier:
First received: September 2, 2009
Last updated: March 12, 2014
Last verified: March 2014
This goal of this study is to evaluate the outcomes from in vitro fertilization cycles where a 450 IU daily dose of gonadotropins is administered compared to those where a 600 IU daily dose is administered for women who are at risk of a poor ovarian response in order to determine if one dose or the other results in improved cycle outcomes.

Condition Intervention Phase
Drug: menotropins for injection
Drug: urofollitropin for injection
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of a Higher Than Maximum 450IU Gonadotropin Dose on Patient Outcomes in an In-Vitro Fertilization Setting: a Randomized Controlled Non-infertility Trial

Resource links provided by NLM:

Further study details as provided by OVO R & D:

Primary Outcome Measures:
  • Number of metaphase II oocytes retrieved during the course of one treatment cycle [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • Number of follicles recruited per patient during stimulation [ Time Frame: 2 years ]
  • Fertilization rate per patient (number of normally fertilized (with 2 pronuclei) oocytes/number of mature oocytes collected) [ Time Frame: 2 years ]
  • Embryo cleavage rate per patient (number of divided normally fertilized oocytes/number of normally fertilized oocytes) [ Time Frame: 2 years ]
  • Number of embryos available per patient [ Time Frame: 2 years ]
  • Number of supernumerary embryos available for cryopreservation per patient [ Time Frame: 2 years ]
  • Implantation rate [ Time Frame: 2 years ]
  • Biochemical pregnancy rate [ Time Frame: 2 years ]
  • Clinical pregnancy rate [ Time Frame: 2 years ]
  • Rate of multiple gestation [ Time Frame: 2 years ]
  • Ongoing pregnancy rate [ Time Frame: 2 years ]
  • Live birth rate [ Time Frame: 2 years ]
  • rate of occurrence of ovarian hyperstimulation syndrome (OHSS) [ Time Frame: 2 years ]

Enrollment: 366
Study Start Date: September 2009
Study Completion Date: February 2014
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 450 IU daily dose of gonadotrophin Drug: menotropins for injection
comparison of different dosages
Other Name: Menopur
Drug: urofollitropin for injection
comparison of different dosages
Other Name: Bravelle
Experimental: 600 IU daily dose of gonadotrophin Drug: menotropins for injection
comparison of different dosages
Other Name: Menopur
Drug: urofollitropin for injection
comparison of different dosages
Other Name: Bravelle


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Premenopausal
  • Age 40 years or less at the time of enrollment
  • At risk of a poor ovarian response defined as: either <5 oocytes or <8 follicles in a previous cycle, FSH > 10 IU/L, AMH < 1 pg/ml , antral follicle count less or equal to 8 or previous IVF cancellation
  • Primary infertility or secondary
  • Not previously undertaken a cycle that was included in this study

Exclusion Criteria:

  • Simultaneous participation in another clinical trial
  • Body mass index (BMI) > 38 kg/m2
  • Early follicular phase (day 2-4) serum FSH level > 20 mIU/ml
  • Any contraindication to being pregnant and carrying a pregnancy to term
  • Contraindication for the use of Estrace® , Suprefact®, Menopur®, Bravelle®, hCG, and luteal phase support medication
  • Any ovarian or abdominal abnormality that may interfere with adequate transvaginal ultrasound evaluation
  • Administration of any investigational drugs within three months prior to study enrollment
  • Patient not able to communicate adequately with the investigators and to comply with the requirements of the entire study
  • Positive results of screening of either partner for HIV antibodies, Hepatitis B (other than for surface antibodies present after vaccination) or Hepatitis C
  • Unwillingness to give written informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00971152

Canada, Quebec
Ovo Fertilité
Montreal, Quebec, Canada, H4P 2S4
Sponsors and Collaborators
Ferring Pharmaceuticals
Principal Investigator: Louise Lapensee, MD OVO Fertilité
Study Director: Jacques Kadoch, MD OVO Fertilité and OVO R & D
  More Information

Additional Information:
Srouji SS, Missmer SA, Ginsburg ES (2004) Impact of increasing gonadotropins > 450 IU on cycle outcome. Brigham and Women's Hospital, Boston, MA. Fertil Steril 82 (Suppl 2): P292.
Flisser E, Krey LC, Berkeley AS (2005) Diminishing Returns of Increasing Gonadotropin Dosage in Subsequent In Vitro Fertilization (IVF) Cycles?. Fertil Steril 84 (Suppl 1) P483.

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: OVO R & D Identifier: NCT00971152     History of Changes
Other Study ID Numbers: F-GYN-08-02
Study First Received: September 2, 2009
Last Updated: March 12, 2014

Keywords provided by OVO R & D:
dose comparison of gonadotrophins
poor responder to ovarian stimulation

Additional relevant MeSH terms:
Genital Diseases, Male
Genital Diseases, Female processed this record on May 22, 2017